EBMT 2024 | Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters
• 15 Apr 2024
In this video, Christina Peters, MD, St. Anna Children’s Hospital, Vienna, Austria, discusses the challenge of managing relapse in patients with acute lymphoblastic leukemia (ALL). Dr Peters first comments on the important role of allogeneic stem cell transplant (allo-SCT), as well as CAR-T cells and NK-cell therapy for these patients. Following this, Dr Peters highlights the impact that conditioning regimens have on patient outcome, which has been demonstrated in the FORUM trial (NCT01949129). This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
